Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS)

Vicarious Surgical reported a narrower Q2 2025 non-GAAP loss of $2.23 per share, beating analyst estimates. The company remains pre-commercial, with no revenue and continued focus on securing FDA approval for its robotic surgical system.